Saturday 17 October 2026 Export LUNG’s income statement to Excel — free account

Pulmonx Corporation

Pulmonx Corporation’s revenue for fiscal 2025 (year ended December 2025) was $90.5 million, up 8.01% from fiscal 2024. In the quarter to June 2026, revenue fell 4.62%, EPS grew 36.8%, free cash flow fell 31.8% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

1.78 0.07 −3.78%

Follow LUNG

Alert me

Market cap: $79.5M
P/E: 0.0×
Fwd P/E: −1.3×
Dividend yield: —
F-score: 3/9
Altman Z: −4.84
Beneish M: −3.38
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.55

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	4	—	—	4	—	—	4	—	—	4	—

Insider Ownership 9.46%

Capital & Financial Ratios $m

Market Cap 79.46

Revenue 87.44

Net Income (48.12)

Free Cash Flow (30.67)

Net Debt (18.67)

Current Ratio 4.32

Debt/Equity 0.95

P/E ratio 0.00

Fwd P/E (1.34)

P/S ratio 0.86

P/B ratio 1.93

Past 5Y EPS Growth —

This Y EPS Growth 21.50%

Next Y EPS Growth 9.78%

Next Y revenue growth 0.06%

Next 5Y EPS Growth 16.56%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 14.62%

10-year low 10-year high

P/B against its own 10 years 24.40%

10-year low 10-year high

EV/Sales against its own 10 years 16.73%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	117	102	70	56
Receivables	12	13	12	12
Inventory	17	17	16	16
Other	—	—	—	—
	150	136	102	88

	2023	2024	2025	Q'26
Payables	1	4	4	5
ST’ Debt	2	3	—	—
Other	—	—	—	—
	23	24	20	20

Compound Annual Growth %

	10y	5y	3y
Sales	—	22.55%	19.03%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(24.87%)	(29.43%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	21	23	—	—	—
’25	23	24	22	23	90
’24	19	21	20	24	84
’23	15	17	18	19	69
’22	11	14	14	15	54
’21	9	12	13	14	48
’20	9	4	11	10	33

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(10)	(5)	—	—	—
’25	(13)	(4)	(8)	(7)	(32)
’24	(12)	(6)	(7)	(7)	(32)
’23	(13)	(8)	(9)	(8)	(38)
’22	(15)	(10)	(11)	(10)	(45)
’21	(10)	(13)	(8)	(11)	(41)
’20	(10)	(8)	(6)	(7)	(31)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(10)	(5)	—	—	—
’25	(14)	(4)	(8)	(7)	(33)
’24	(12)	(6)	(8)	(7)	(33)
’23	(13)	(8)	(9)	(9)	(38)
’22	(16)	(10)	(11)	(10)	(46)
’21	(10)	(13)	(10)	(12)	(45)
’20	(10)	(8)	(6)	(8)	(32)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.33)	(0.24)	—	—	—
’25	(0.36)	(0.38)	(0.34)	(0.25)	(1.33)
’24	(0.36)	(0.39)	(0.36)	(0.33)	(1.44)
’23	(0.42)	(0.43)	(0.39)	(0.36)	(1.60)
’22	(0.43)	(0.40)	(0.38)	(0.38)	(1.59)
’21	(0.34)	(0.34)	(0.28)	(0.35)	(1.35)
’20	(3.76)	(6.16)	(1.37)	(0.27)	(3.16)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	37.64	28.87	4.07	7.23	5.46	1.31	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	69.48	68.76	36.26	14.28	14.84	9.37
People
People	Employees	—	—	—	202	170	160	269	279	291	296
	Revenue/emp, $m	—	—	0.00	0.16	0.19	0.30	0.20	0.25	0.29	0.31
Income, $m
Income, $m	Revenue	—	—	20	33	33	48	54	69	84	90
	Gross margin, %	—	—	61.42	68.77	64.77	73.59	74.29	73.90	74.00	74.19
	EBT	—	—	(18)	(20)	(32)	(48)	(59)	(60)	(56)	(53)
	EBT margin, %	—	—	(92.32)	(62.40)	(97.82)	(99.80)	(109.15)	(87.76)	(66.71)	(58.98)
	Net income	—	0	(18)	(21)	(32)	(49)	(59)	(61)	(56)	(54)
	Depreciation	—	—	0	0	1	1	1	1	0	1
Per share, $
Per share, $	Revenue	—	—	11.94	18.35	3.21	1.34	1.45	1.81	2.14	2.22
	Earnings	—	—	(11.03)	(11.66)	(3.16)	(1.35)	(1.59)	(1.60)	(1.44)	(1.33)
	Cash flow	—	—	(10.98)	(11.69)	(3.01)	(1.15)	(1.22)	(0.99)	(0.81)	(0.80)
	Capex	—	—	(0.18)	(0.41)	(0.09)	(0.10)	(0.04)	(0.02)	(0.04)	(0.01)
	Free cash flow	—	—	(11.16)	(12.10)	(3.10)	(1.25)	(1.25)	(1.01)	(0.84)	(0.81)
	Book value	—	—	(15.99)	10.11	22.20	5.35	4.15	3.12	2.19	1.33
	Shares, m	—	—	2	2	10	36	37	38	39	41
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	3.33	3.33	21.48	23.93	5.18	7.02	3.17	0.99
	P/B	—	—	0.00	0.00	3.11	6.00	1.80	4.08	3.09	1.66
	EV/Sales	—	—	3.58	3.58	14.98	20.61	2.87	5.86	2.40	0.63
	EV/FCF	—	—	(4.36)	(4.36)	(15.54)	(22.15)	(3.31)	(10.47)	(6.09)	(1.74)
Cash, $m
Cash, $m	Operating cash flow	—	—	(18)	(21)	(31)	(41)	(45)	(38)	(32)	(32)
	Capex	—	—	0	(1)	(1)	(4)	(1)	(1)	(1)	0
	Free cash flow	—	—	(19)	(21)	(32)	(45)	(46)	(38)	(33)	(33)
Balance, $m
Balance, $m	Working capital	—	—	3	27	237	190	150	127	112	82
	Total debt	—	—	34	15	19	20	17	37	37	37
	Net debt	—	—	29	(13)	(213)	(161)	(124)	(80)	(65)	(33)
	Shareholders’ equity	—	—	(27)	18	226	193	154	118	86	54
Returns, %
Returns, %	ROA	—	—	(246.17)	(60.41)	(20.32)	(19.51)	(27.48)	(32.76)	(33.11)	(36.97)
	ROIC	—	—	(349.72)	(221.87)	(150.98)	(90.74)	(122.32)	(101.28)	(169.73)	(158.98)
	ROE	—	—	10.42	11.67	(166.33)	(23.21)	(33.94)	(44.68)	(55.25)	(77.19)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
APYX Apyx Medical Corporation	$107.8M	— (loss-making)	— (loss-making)	+22.08% (above 0%: growing)	n/m	−137.38% (below 0%: shrinking)	63.89%	(13.01%)	Compare
LUCD Lucid Diagnostics Inc.	$105.7M	— (loss-making)	— (loss-making)	+26.74% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	1.97%	(868.45%)	Compare
ZOMDF Zomedica Corp.	$95.4M	— (loss-making)	— (loss-making)	+36.59% (above 0%: growing)	n/m	+40.48% (above 0%: growing)	63.51%	(42.92%)	Compare
HYPR Hyperfine, Inc.	$82.7M	— (loss-making)	— (loss-making)	+44.81% (above 0%: growing)	n/m	+13.43% (above 0%: growing)	50.72%	(216.93%)	Compare
SERA Sera Prognostics, Inc.	$80.1M	— (loss-making)	— (loss-making)	+76.47% (above 0%: growing)	n/m	−10.58% (below 0%: shrinking)	(66.67%)	(33,346.67%)	Compare
LUNG Pulmonx Corporation	$79.5M	— (loss-making)	— (loss-making)	−4.62% (below 0%: shrinking)	n/m	−31.79% (below 0%: shrinking)	77.97%	(39.80%)
OM Outset Medical, Inc.	$76.6M	— (loss-making)	— (loss-making)	+0.69% (above 0%: growing)	n/m	−90.54% (below 0%: shrinking)	41.99%	(49.55%)	Compare
ECOR electroCore, Inc.	$75.3M	— (loss-making)	— (loss-making)	+28.03% (above 0%: growing)	n/m	−443.52% (below 0%: shrinking)	86.53%	(29.33%)	Compare
LNSR LENSAR, Inc.	$74.1M	2.0×	7.1×	+18.37% (above 0%: growing)	n/m	+96.81% (above 0%: growing)	59.27%	12.94%	Compare
Median of peers	$81.4M	—	—	+27.39%	—	−8.81%	54.99%	(46.24%)

All 149 Medical Devices stocks →

Pulmonx Corporation (LUNG) key facts

Concern: Pulmonx Corporation reported a net loss of $54.0 million, or a loss of $1.33 per share, for fiscal 2025.
Strength: Pulmonx Corporation’s revenue for fiscal 2025 (year ended December 2025) was $90.5 million, up 8.01% from fiscal 2024.
Pulmonx Corporation (LUNG) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, LUNG traded at $1.78, a market capitalization of $79.5 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.9× sales.
Return on equity was −77.2% and debt-to-equity 0.95.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −4.84 (distress zone) for fiscal 2025.